WO2004113570A2 - Essai de genotype - Google Patents

Essai de genotype Download PDF

Info

Publication number
WO2004113570A2
WO2004113570A2 PCT/GB2004/002559 GB2004002559W WO2004113570A2 WO 2004113570 A2 WO2004113570 A2 WO 2004113570A2 GB 2004002559 W GB2004002559 W GB 2004002559W WO 2004113570 A2 WO2004113570 A2 WO 2004113570A2
Authority
WO
WIPO (PCT)
Prior art keywords
dog
breed
food
breeds
specific
Prior art date
Application number
PCT/GB2004/002559
Other languages
English (en)
Other versions
WO2004113570A3 (fr
Inventor
Paul Glyn Jones
Neale Fretwell
Original Assignee
Mars, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars, Incorporated filed Critical Mars, Incorporated
Priority to JP2006516424A priority Critical patent/JP2007528205A/ja
Priority to EP04736923A priority patent/EP1636377A2/fr
Priority to AU2004249943A priority patent/AU2004249943B8/en
Publication of WO2004113570A2 publication Critical patent/WO2004113570A2/fr
Publication of WO2004113570A3 publication Critical patent/WO2004113570A3/fr
Priority to US11/303,853 priority patent/US20060147962A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Definitions

  • the invention relates to a method for determining the nutritional, medical or behavioural needs of a dog.
  • the domestic dog (Canis fam ⁇ liaris) species comprises a large number of distinct breeds. Hundreds of different dog breeds have been established. Popular dog breeds include Labrador retrievers, Golden retrievers, German shepherds, Verbshunds, Shih Tzu, England terriers, Poodles, Rottweilers, Boxers and Cocker spaniels.
  • Dog breeds typically differ in size, conformation, behaviour and physiology. Different breeds can vary in size by as much as two orders of magnitude, and have differing metabolic and nutritional requirements. Particular dog breeds also have food sensitivities or predisposition to disease, which require preventative treatments and/or diets. Differences also exist in the digestibility of nutrients among breeds.
  • the invention allows the determination of the needs and characteristics of a dog, based on detection of SNPs (single nucleotide polymorphisms) in the dog.
  • SNPs single nucleotide polymorphisms
  • the invention takes advantage of the breed structure of the dog population to provide a genetic test for determining the nutritional, medical and behavioural needs of a dog by detecting particular SNPs in the dog. These needs may be ones for which the underlying genetic basis is unknown.
  • the genetic test of the invention thus allows knowledge of breed-specific characteristics to be applied to addressing the specific needs of a dog.
  • the invention additionally provides SNP sequences that can be used in the genetic test.
  • the invention provides: a method for assessing a nutritional requirement, disease susceptibility or behavioural characteristic of a dog, the method comprising:
  • identifying therefrom the genetic breed inheritance of the dog an isolated polynucleotide that comprises a sequence of any one of SEQ ID NO:s 1 or 4 to 23 or a polypeptide encoded by any one of SEQ ID NO:s 1 or 4 to 23 ; a probe, primer or antibody which is capable of detecting a polynucleotide or polypeptide according to the present invention; a kit for carrying out the method of the invention, comprising means for detecting the nucleotide present at one or more breed-specific SNP positions; use of means for detecting the nucleotide present at one or more breed- specific SNP positions for determining a nutritional requirement, disease susceptibility or behavioural characteristic of a dog; a method of identifying one or more SNP marker(s) which can be used to determine the breed inheritance of a dog, the method comprising:
  • a module for comparing the data with a database comprising information relating to breed-specific genomic SNPs and the nutritional requirements, disease susceptibility or behavioural characteristics of the breeds;
  • (iii) means for determining on the basis of said comparison the breed inheritance of the dog; use of a computer system according to the present invention to make a customised dog food product.
  • Figure 1 illustrates schematically an embodiment of functional components arranged to carry out the present invention.
  • SEQ ID NO: 1 sets out the nucleic acid sequence of the English Mastiff mast cell chymase gene containing the C5375T SNP.
  • SEQ ID NO: 2 sets out the sequence of the forward primer used to amplify the English Mastiff mast cell chymase gene sequence containing the C5375T SNP.
  • SEQ ID NO: 3 sets out the sequence of the reverse primer used to amplify the English Mastiff mast cell chymase gene sequence containing the C5375T SNP.
  • SEQ ID NO: 4 sets out the RAGE_8Kb_6000 contig nucleic acid sequence.
  • SEQ ID NO: 5 sets out the RAGE_8Kb_6002 contig nucleic acid sequence.
  • SEQ ID NO: 6 sets out the RAGE_8Kb_5959 contig nucleic acid sequence.
  • SEQ ID NO: 7 sets out the FCGR3B_7.42Kb_5238 contig nucleic acid sequence.
  • SEQ ID NO: 8 sets out the PAIl_10Kb_2979 contig nucleic acid sequence.
  • SEQ ID NO: 9 sets out the RAGE_8Kb_6006 contig nucleic acid sequence.
  • SEQ ID NO: 10 sets out the FCGR3B_7.42Kb_5264 contig nucleic acid sequence.
  • SEQ ID NO: 11 sets out the FCGR3B_7.42Kb_5137 contig nucleic acid sequence.
  • SEQ ID NO: 12 sets out the FCGR3B_7.42Kb_5002 contig nucleic acid sequence.
  • SEQ ID NO: 13 sets out the FCGR3B_7.42Kb_5167 contig nucleic acid sequence.
  • SEQ ID NO: 14 sets out the RAGE_8Kb_5820 contig nucleic acid sequence.
  • SEQ ID NO: 15 sets out the FCGR2A_9.86Kb_8708 contig nucleic acid sequence.
  • SEQ ID NO: 16 sets out the RAGE_8Kb_5847 contig nucleic acid sequence.
  • SEQ ID NO: 17 sets out the RAGE_5Kb_4329 contig nucleic acid sequence.
  • SEQ ID NO: 18 sets out the RAGE_5Kb_4766 contig nucleic acid sequence.
  • SEQ ID NO: 19 sets out the RAGE_8Kb_6182 contig nucleic acid sequence.
  • SEQ ID NO: 20 sets out the FCGR3B_7.42Kb_5239 contig nucleic acid sequence.
  • SEQ ID NO: 21 sets out the RAGE_8Kb_5771 contig nucleic acid sequence.
  • SEQ ID NO: 22 sets out the RAGE_5Kb_4805 contig nucleic acid sequence.
  • SEQ ID NO: 23 sets out the FCGR3B_7.42Kb_4947 contig nucleic acid sequence.
  • the present invention allows the identification of the nutritional requirements, disease susceptibility or behavioural characteristics of a dog by determination of its breed ancestry. Detection of the presence or absence of SNP markers in the dog allows identification of the breeds that have contributed to the dog's genome (i.e. its genetic breed inheritance), allowing the genetic background of the dbg to be deduced.
  • a breed is a homogeneous group of animals within a species, which has been developed by man. Dog breeds are normally divided into seven categories, based on the uses for which the breeds were originally developed. The seven dog breed categories and examples of specific breeds that fall within each category are shown in Table 1.
  • a "breed-specific SNP” is a single nucleotide polymorphism that can be used to distinguish between different dog breeds or to determine breed inheritance, either alone or in combination with other SNPs. Such a breed-specific SNP may be unique to one breed. Alternatively, a breed-specific SNP may be present in a plurality of breeds, but its presence in combination with one or more other breed- specific SNPs can be used to determine a dog's genetic breed inheritance. In one embodiment of the invention, the SNP is present in substantially all dogs of one breed, and is absent in substantially all dogs of other breeds. The breed-specificity of a SNP is typically assessed in a sample population of a breed that is representative of that breed.
  • sample population will typically consist only of purebred dogs.
  • the sample population typically comprises 4 or more dogs per breed, such as at least 20, 100, 400, 1000 or 10,000 dogs of one breed.
  • the sample population tested for the SNP may be up to 10, 200, 500, 1000, 10,000 or 1,000,000 or more dogs.
  • the sample population may consist of from 4 to 10,000, for example 20 to 1000, or 100 to 500 dogs per breed.
  • the sample population may be from 200 to 400 dogs per breed.
  • a breed-specific SNP is typically present in 70%, 80% or 90% or more of the sample population of that breed, preferably 95% or more of the sample population, more preferably 99% or more of the sample population.
  • the breed-specific SNP is typically absent in substantially all dogs of sample populations of other breeds.
  • a breed specific SNP may be present in 30%, 20% or 10% or less of a sample population of another breed, preferably 5% or less of the sample population, more preferably 1% or less of the sample population.
  • the SNP is present in at least 95% of dogs in a sample population of from 400 to 1000 dogs of a breed and/or is present in 5% or less dogs in a sample population of from 400 to 1000 dogs of any other breed.
  • the breed- specific SNP will be unique to that breed, i.e. it will be present in 100%) of dogs in a sample population which is representative of that breed and will be entirely absent from dogs in a sample population which is representative of any other breed.
  • the SNP may be specific for a breed category shown in Table 1.
  • the SNP marker may be specific for Hound breeds such as the Beagle, Bloodhound, Whippet or Greyhound.
  • the SNP marker may be specific for Working dogs, such as the Boxer, Great Dane and St Bernard.
  • the SNP marker may be specific for dogs in the Terrier group, such as the West Highland White Terrier and the Airedale Terrier.
  • the SNP marker may be specific for breeds in the Utility, or Non-Sporting, group such as the Bulldog, Dalmatian and Poodle.
  • the SNP marker may be specific for Toy dog breeds such as the Chihuahua and Shih Tzu.
  • the SNP is specific to a family or subgroup of breeds within a breed category.
  • the SNP may be specific for Gundogs, or Sporting group dogs. This category is divided into four sub-groups: Retriever, Dogls, Hunt/Point/Retrieve and Setters.
  • the SNP marker may be specific for any one or more of these four sub-groups.
  • the SNP marker may be specific for dogs in the Pastoral, or Herding, group.
  • This breed category includes the Collie family of breeds and Shepherd dogs. Hence the SNP may be specific, for the Collie family and/or Shepherd dogs.
  • the breed-specific SNP can be used to distinguish one breed of dog in a panel of dog breeds from the other breeds in the panel.
  • the panel may consist of from 2 to 400 breeds, for example from 2 to 200, from 5 to 100, from 5 to 30, from 5 to 20, fromlO to 15, from 2 to 10 or from 5 to 10 breeds.
  • the SNP marker is thus specific for one of the breeds in the panel.
  • the SNP marker may actually be found in more than one breed, for example for 2, 3, 5, 10 or more breeds. However, according to this particular embodiment, it will be specific for only one of the breeds in the panel.
  • the breeds can be selected from any of the categories shown in Table 1 above.
  • a SNP that is specific for two or more breeds within a breed category can be used to distinguish those particular breeds from other breeds in the breed category.
  • the SNP marker is present only in one breed (i.e. it is unique to that breed compared to all other breeds).
  • each breed is not defined by a single SNP, but by the combination of SNPs present in the dog genome. Accordingly, the genetic breed inheritance of a dog may be identified from a combination of the nucleotides present at two or more SNP positions, for example at three or more, four or more, five or more, or six or more SNP positions. Each dog breed may therefore be defined by a set of rules based on the combination of nucleotides found at each of these SNP positions. In some cases, in order to define a breed it may be necessary to provide one or more rules which specify the nucleotide found at least 7, 8, 9, 10, 11, 12, 15 or 20 or more SNP positions.
  • each dog breed may be defined by a single rule or more than one rule, for example by 2, 3, 4, 5, 10, 20 or more rules.
  • typically at least 2 different SNP positions are typed, for example at least 3, 4, 5, 6, 7, 8, 9 or 10 or more positions, preferably at least 20 different SNP positions.
  • up to 10, 15, 20, 25, 30, 50 or 100 positions will be typed, for example 10 to 50, or 10 to 25 positions.
  • the term "typed" typically comprises determining the nucleotide present at any given SNP position.
  • the term "genetic breed inheritance” is used herein to describe the breed ancestry of a dog, namely the one or more breeds that have contributed to the dog's genome. Therefore, in the case of a purebred dog, the term “genetic breed inheritance” will typically correspond to the breed of the dog. Accordingly, in one embodiment of the invention the nucleotide present at one or SNP positions in the dog's genome can be used to determine the breed of the dog. In the case of a crossbred or outbred dog, the term “genetic breed inheritance” may relate to the one or more breeds that are represented in the dog's lineage. This term may further be used to describe the proportions or relative amounts of each breed that goes to make up a mongrel dog.
  • the method of the invention can be used to detect a genetic breed inheritance from any number of different dog breeds, such as at least 2, 3, 4, 5, 10, 20, 50, 70, 100 or 400 or more different dog breeds.
  • the nucleotide present at one or more SNP positions is used to distinguish between the following breeds: Labrador retriever, Golden retriever, German Shepherd, Verbshund, Shih Tzu, England terrier, Poodle, Rottweiler, Boxer and Cocker spaniel.
  • the present invention enables the determination of a nutritional requirement, disease susceptibility or behavioural characteristic of a dog, the method comprising determining the nucleotide present at one or more breed-specific SNP (single nucleotide polymorphism) positions in the dog genome and thereby determining the breed inheritance of the dog.
  • a method for determining the breed inheritance of a dog according to the invention may be carried out by electronic means, for example by using a computer system.
  • the presence of a breed-specific SNP in a dog indicates that it has a genetic inheritance in common with that breed, and therefore is likely to share that breed's characteristics regarding nutritional requirements, disease susceptibility and behavioural characteristics.
  • the absence of a particular breed- specific SNP indicates that the dog does not have any genetic inheritance from that breed.
  • a method for determining the nutritional requirements, disease susceptibility or behavioural characteristics of a dog according to the invention may be carried out by electronic means, for example by using a computer system.
  • Dog breeds differ from each other in (for example) size, weight, shape, digestive transit time, growth period, temperament, activity level, life span, coat type, nutritional requirements and disease susceptibility. Table 1 illustrates some of these differences.
  • the nutritional requirement, disease susceptibility or behavioural characteristic assessed by the method of the invention may be any such nutritional, medical or behavioural need mentioned herein, such as those in Table 1 or those discussed below.
  • Bodyweight size in dog breeds can be grouped into 5 categories (from smallest to largest): toy, small, medium, large and giant (or extra large). Breeds also differ in the ratio of gastrointestinal weight: total bodyweight. In small breeds, the digestive tract represents 7% of their total bodyweight, whilst for giant breeds this is only 2.7%). Digestive transit time also varies depending on the size of the dog, and can vary from 15 hours to 4 days. The growth period of a dog varies by breed, is determined by feeding regime and feeding rate, and lasts between approximately 8 months for a small breed to up to 24 months for a giant breed. Small breeds have a much greater growth rate than large breeds. Small breed puppies typically multiply their birth weight by approximately 20 times during their first year of life. This ratio can be as great as 100 times for giant breeds. The size of a dog also affects its life expectancy. The larger and heavier the dog, the earlier the aging process begins. Life expectancy for giant breeds is generally half that of small breeds.
  • Other, well-recognised problems include vitamin A responsive dermatitis in Cocker Dogs and zinc-responsive dermatitis in Siberian Huskies and Alaskan Malamutes.
  • Some Cocker Dogs and Golden Retrievers have low blood taurine levels which are responsive to dietary taraine supplements.
  • the dog that is tested may be a crossbred or outbred (mongrel) dog.
  • a crossbred dog is the offspring of two different purebred dogs.
  • An outbred or mongrel dog is a dog of unknown parentage, or is the result of the combination of three or more different breeds.
  • An outbred dog may therefore represent a mixture of 3 or more breeds, for example, 4, 5 or more different breeds.
  • the breeds that contribute to an outbred dog's genetic breed inheritance may be from within the same category of breed or from different breed categories.
  • a mongrel will typically display a combination of physical characteristics that are not found within one particular breed, such as any characteristics mentioned herein, for example size, shape, colour, coat type, stature, gait, height or head shape.
  • an outbred dog may have the size and shape of one breed, but have the colour or coat type of a different breed. Therefore, the method of the invention may be used to identify the genetic breed inheritance of a dog which has a mixture of characteristics typically found in different breeds.
  • the method may be used to determine the genetic background of a dog which has the physical features of a mongrel, or is suspected of being a mongrel.
  • the method of the invention may also be used to identify or to confirm the genetic background of a crossbred dog.
  • the present invention provides a means of determining a nutritional requirement of a dog, based on its genetic breed inheritance.
  • a nutritional requirement is any such requirement mentioned herein, for example as discussed below.
  • the requirement typically relates to the proportions, total amounts or types of vitamins, minerals, fat, carbohydrates, fibre, protein and water required.
  • the requirement may relate to whether or not the dog requires or needs to avoid particular food components.
  • the protein requirement of a dog may relate to the total amount of protein or type of protein needed, as defined by the protein source or amino acid composition.
  • the essential amino acids for dogs include lysine, arginine, histidine, isoleucine, leucine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan and valine.
  • Essential amino acids cannot be synthesized by the dog, and so must be present in its food.
  • the amount of each amino acid required may vary.
  • the dog may have a requirement for an amino acid such as taurine.
  • the dog's nutritional requirements may concern the source of protein, for example, whether the protein is derived from meat, poultry, dairy, vegetable or other protein sources.
  • protein sources may be defined as high or low quality protein sources.
  • quality is defined by digestibility and amino acid content.
  • a high quality protein source such as animal protein
  • a low quality protein source such as vegetable protein
  • the dog's nutritional requirement may further relate to the amount of fat needed by the dog or to a particular type of fat that is required. Fats are typically saturated, polyunsaturated or monounsaturated. A dog may require different amounts of each type of fat, or only one or more of these types of fat. For example, the nutritional requirement may be for polyunsaturated or monounsaturated fats only. Fats also differ in their fatty acid composition. The nutritional requirement may relate to particular fatty acids, such as essential fatty acids, which cannot be made within the dog's body and so have to be provided in the diet.
  • the essential fatty acids may be classified as omega-6 and omega-3 fatty acids, such as linoleic, linolenic and arachidonic acids, for example, gamma linolenic acid (GLA).
  • omega-6 and omega-3 fatty acids such as linoleic, linolenic and arachidonic acids, for example, gamma linolenic acid (GLA).
  • GLA gamma linolenic acid
  • these polyunsaturated fatty acids vary in the number of carbon atoms and the degree of unsaturation, and may be classified as short-chain and long-chain fatty acids.
  • the nutritional requirement may relate to the absolute amounts of these fatty acids, or to the ratio of omega-6 to omega-3 fatty acids.
  • the dog's nutritional requirement may relate to the total amounts or proportions of vitamins or minerals needed.
  • Vitamins may be divided into two main categories: fat soluble and water soluble.
  • the fat soluble vitamins include vitamins A, D, E and K.
  • the water soluble vitamins include vitamins Bl, B2, B6, B12, biotin, choline, pantothenic acid, nicotinic acid and folic acid.
  • a dog may require particular levels of each vitamin.
  • Minerals can be divided into two groups: macro-minerals and trace minerals. Macro-minerals include calcium, phosphorus, magnesium, sodium, potassium and chloride. Trace minerals include iron, zinc, copper, manganese, cobalt, selenium and iodine.
  • the nutritional requirement of the dog may relate to the total amounts of each mineral or to the ratio between the minerals needed. For example, the nutritional requirement may relate to the ratio between calcium and phosphorus.
  • the dog's nutritional requirement may relate to the amount of carbohydrate or to the type of carbohydrate needed.
  • Carbohydrates can be classified according to the glycemic index, which measures the ability of a food to elevate blood glucose levels. Carbohydrates with a high glycemic index enter the bloodstream quickly, whereas those with a low glycemic index enter the bloodstream slowly and provide sustained, longer-term energy.
  • the glycemic index of a food is typically given in relation to glucose (or maltose), which has a nominal value of 100.
  • glucose or maltose
  • barley has a lower glycemic index than other grains such as corn, wheat or rice.
  • the dog's nutritional requirements may relate to the glycemic index of carbohydrate that is required.
  • the nutritional requirement may further relate to the amount or proportion of fibre or the type of fibre needed.
  • fibre may be derived from different sources, such as fruit, vegetable or grains. Different types of fibre may differ in how quickly they are fermented. For example, fruit and vegetable fibres are moderately fermented whereas grain fibres are more slowly fermented.
  • the nutritional requirement of the dog may concern its metabolic or energy requirements.
  • the energy requirement of the dog typically relates to its size and activity level.
  • a large dog generally requires a greater total amount of energy than a small dog, and an active dog will normally require more energy than an inactive dog.
  • a dog may have low activity ( ⁇ 1 hour per day), moderate activity (1-2 hours per day), moderate to high activity (2-3 hours per day) or high activity (>3 hours per day).
  • the energy requirement is usually expressed as either kilocalories (kcal) or kilojoules (kJ).
  • the nutritional requirement may be determined on a daily, weekly basis or a monthly basis.
  • the dog's nutritional requirements will be determined on a daily basis, for example as a recommended daily amount (RDA) of a nutrient.
  • the energy requirement of the dog will typically be determined on a daily basis.
  • the nutritional requirement of the dog may relate to food allergies or intolerance. Allergens for dogs typically fall into one of four groups: (i) milk, eggs, soy, wheat (gluten), peanuts, shellfish, fruits, tree nuts; (ii) sesame seeds, sunflower seeds, cottonseed, poppy seed, beans, peas, lentils; (iii) tartrazine, sulphites and latex; and (iv) salicylate, amines and glutamate. The most common food allergies are to those foods in group (i).
  • the present invention allows for determination of a disease susceptibility of a dog, based on its genetic breed inheritance.
  • Narious dog breeds have susceptibility to different diseases and conditions.
  • diseases or conditions may be cardiovascular, inflammatory, immunological, infectious, metabolic, endocrine or gastrointestinal in nature.
  • the disease or condition may be any of the diseases or conditions mentioned herein.
  • German Shepherd dogs commonly suffer from hip dysplasia, epilepsy, gastric torsion (bloat), perianal fistulas and exocrine pancreatic deficiency.
  • Labrador Retrievers are particularly susceptible to hip, elbow and retinal dysplasia, obesity and exercise-induced collapse. Golden Retrievers are also prone to hip dysplasia, and sometimes experience skin and coat problems such as pyotraumatic dermatitis (hotspots).
  • Cocker Spaniels commonly suffer from hereditary eye problems (such as PRA, cataracts, glaucoma, eyelid, eyelash and retinal abnormalities), skin conditions, hemophilia, ear infections (such as otitis externa), heart disease and epilepsy. Boxers are prone to tumours, digestive problems, heart disease, corneal ulcers, skin fold infections and bloat. Rottweilers are susceptible to hip and elbow dysplasia, osteochonsrosis dessicans, panosteitis, entropieon (inverted eyelids), hypothyroidism, von Willebrand's disease and bloat.
  • Shih Tzu dogs commonly suffer from slipped stifle (a joint disorder) and renal dysplasia. Poodles are prone to hip dyslplasia, PRA, cataracts, epilepsy, bloat, von Willebrand's disease, skin disorders and autoimmune disorders.
  • a behavioural characteristic of a dog may be determined.
  • different dog breeds have different activity levels and temperament. Accordingly, dogs differ in the type of environment that is suitable for them. For example, dogs have differing requirements for space, locality (e.g. town or countryside), exercise, grooming and attention. Dog breeds also differ in their trainability, people fear, aggressiveness, alertness and cognitive performance. When selecting an appropriate environment for a dog, it is important to bear in mind factors such as their size at maturity and their temperament (e.g. aggressiveness).
  • the behavioural characteristics determined according to the present invention may be any of those in Table 1 or any other characteristics discussed herein.
  • a nutritional requirement, disease susceptibility or behavioural characteristic is determined of a dog that is suspected of having a nutritional, medical or behavioural problem.
  • the dog may be displaying physical or psychological symptoms that are indicative of a nutritional imbalance or deficiency, a disease or behavioural problem.
  • a nutritional or medical problem may be indicated by changes in eye colour, gum and mouth tissue, skin condition, coat condition, energy level or muscle tone in the dog.
  • Other symptoms of a problem may include lethargy, weight loss, bladder control loss, change in water intake, change in faeces quality, appetite loss, sudden behavioural change or alertness change.
  • the detection of SNPs according to the invention may comprise contacting a polynucleotide or protein of the animal with a specific binding agent for a breed- specific SNP and determining whether the agent binds to the polynucleotide or protein.
  • the method is typically it is carried out in vitro on a sample from the dog.
  • the sample typically comprises a body fluid and/or cells of the individual and may, for example, be obtained using a swab, such as a mouth swab.
  • the sample may be a blood, urine, saliva, skin, cheek cell or hair root sample.
  • the sample is typically processed before the method is carried out, for example DNA extraction may be carried out.
  • the polynucleotide or protein in the sample may be cleaved either physically or chemically, for example using a suitable enzyme.
  • the part of polynucleotide in the sample is copied or amplified, for example by cloning or using a PCR based method prior to detecting the SNP marker(s).
  • Tables 2 and 7 show breed-specific SNPs that can be used to type the breed inheritance of a dog.
  • a breed-specific SNP may be a "silent" polymorphism. Such "silent" polymorphisms are those which do not result in a change in amino acid sequence. Only SNPs that change the coding sequence of the nucleic acid sequence may be detected in polypeptide sequences.
  • the polymorphism preferably does not affect the function of the protein in any other way, for example by altering gene expression by changing promoter activity, mRNA stability, mRNA splicing or epigenetic status. Such polymorphisms may or may not be causative of a breed phenotype.
  • the breed-specific SNP is not causative of a nutritional requirement, disease susceptibility or behavioural characteristic of a dog, and is not in linkage disequilibrium with such a SNP.
  • the SNP may however be specific for one or more physical characteristics of a breed, for example size, shape, colour, coat type, stature, gait, height or head shape, or other breed traits or phenotypes.
  • any one or more methods may comprise determining the nucleotide present at one or more breed-specific SNP positions in the dog.
  • the nucleotide present at more than one breed- specific SNP positions is detected, such as at least 2, 3, 5, 10, 15 or 20 or more SNP positions.
  • the one or more SNP positions are any of those identified in SEQ ID NO:s 1 or 4 to 23.
  • the markers which are tested may be specific to a combination of different breeds.
  • the dog is tested for the presence and/or absence of one or more breed-specific SNP markers for at least 2, 3, 5 or 10 different breeds.
  • the markers that are typed are specific for the following breeds: Labrador retriever, Golden retriever, German Shepherd, Verbshund, Shih Tzu, England terrier, Poodle, Rottweiler, Boxer and Cocker spaniel.
  • the breed-specific SNP is present in substantially all dogs of that breed, and is absent in substantially all dogs of other breeds.
  • One or more markers specific for each breed may be typed, for example at least 2, 3, 5 or 10 markers may be tested which are specific for one breed.
  • the breed-specific SNP is typically detected by directly determining the presence of the polymorphic sequence in a polynucleotide or protein of the dog.
  • a polynucleotide is typically genomic DNA, mRNA or cDNA.
  • the SNP may be detected by any suitable method such as those mentioned below.
  • a specific binding agent is an agent that binds with preferential or high affinity to the polynucleotide or polypeptide having a particular nucleotide or amino acid at a SNP position but does not bind or binds with only low affinity to polynucleotides or proteins which have a different nucleotide or amino acid at the same SNP position.
  • the specific binding agent may be a probe or primer.
  • the probe may be a protein (such as an antibody) or an oligonucleotide.
  • the probes or primers will typically also bind to flanking nucleotides and amino acids on one or both sides of the SNP position, for example at least 2, 5, 10, 15 or more flanking nucleotide or amino acids in total or on each side.
  • a probe or primer may be fully or partially complementary to (i.e. have homology with) either all or part of the flanking 5' and/or 3 ' sequences shown in Tables 2 and 7.
  • the probe may be labelled or may be capable of being labelled indirectly.
  • the binding of the probe to the polynucleotide or protein may be used to immobilise either the probe or the polynucleotide or protein.
  • determination of the binding of the agent to the breed-specific SNP can be done by determining the binding of the agent to the polynucleotide or protein of the dog.
  • the agent is also able to bind the corresponding wild-type sequence, for example by binding the nucleotides or amino acids which flank the SNP marker position, although the manner of binding to the wild-type sequence will be detectably different to the binding of a polynucleotide or protein containing the SNP marker.
  • the method may be based on an oligonucleotide ligation assay in which two oligonucleotide probes are used. These probes bind to adjacent areas on the polynucleotide which contains the SNP marker, allowing after binding the two probes to be ligated together by an appropriate ligase enzyme. However the presence of single mismatch within one of the probes may disrupt binding and ligation. Thus ligated probes will only occur with a polynucleotide that contains the SNP marker, and therefore the detection of the ligated product may be used to determine the presence of the SNP marker.
  • the probe is used in a heteroduplex analysis based system.
  • a heteroduplex analysis based system when the probe is bound to polynucleotide sequence containing the SNP marker it forms a heteroduplex at the site where the SNP marker occurs and hence does not form a double strand structure.
  • a heteroduplex structure can be detected by the use of single or double strand specific enzyme.
  • the probe is an RNA probe, the heteroduplex region is cleaved using RNAase H and the SNP marker is detected by detecting the cleavage products.
  • the method may be based on fluorescent chemical cleavage mismatch analysis which is described for example in PCR Methods and Applications 3, 268-71 (1994) and Proc. Natl. Acad. Sci. 85, 4397-4401 (1998).
  • a PCR primer is used that primes a PCR reaction only if it binds a polynucleotide containing the SNP marker, for example a sequence- or allele- specific PCR system, and the presence of the SNP marker may be determined by the detecting the PCR product.
  • the region of the primer which is complementary to the SNP marker is at or near the 3' end of the primer.
  • the presence of the SNP marker may be determined using a fluorescent dye and quenching agent- based PCR assay such as the Taqman PCR detection system.
  • the specific binding agent may be capable of specifically binding the amino acid sequence encoded by a polymorphic sequence, preferably one of the sequences shown in Table 2.
  • the agent may be an antibody or antibody fragment.
  • the detection method may be based on an ELISA system.
  • the method may be an RFLP based system. This can be used if the presence of the SNP marker in the polynucleotide creates or destroys a restriction site that is recognised by a restriction enzyme.
  • the presence of the SNP marker may be determined based on the change which the presence of the SNP marker makes to the mobility of the polynucleotide or protein during gel electrophoresis.
  • SSCP polynucleotide single-stranded conformation SNP marker
  • DDGE denaturing gradient gel electrophoresis
  • a polynucleotide comprising the polymorphic region is sequenced across the region which contains the SNP marker to determine the presence of the SNP marker.
  • the invention also provides a polynucleotide which comprises a breed-specific SNP.
  • the SNP position is any one of those identified in any one of SEQ ID NO:s 1 or 4 to 23.
  • the polynucleotide is typically at least 10, 15, 20, 30, 50, 100, 200 or 500 bases long, such as at least or up to lkb, lOkb, lOOkb, 1000 kb or more in length.
  • the polynucleotide will typically comprise flanking nucleotides on one or both sides of (5' or 3' to) the SNP position, for example at least 2, 5, 10, 15 or more flanking nucleotides in total or on each side.
  • flanking sequences of the 5' or 3' side may be fully or partially identical to or fully or partially complementary to (i.e. have homology with) either all or part of the flanking 5' and/or 3' sequences identified in any one of SEQ ID NO:s 1 or 4 to 23.
  • the polynucleotide may differ to the sequences identified in any one of SEQ ID NO:s 1 or 4 to 23 by less than 30, 20, 10, 5, 3 or 2 substitutions and/or insertions and/or deletions in sequence, apart from at the polymorphic position.
  • the polynucleotide will be at least 95%o, preferably at least 99%, even more preferably at least 99.9%) identical to the sequence comprising the SNP position as identified in any one of SEQ ID NO:s 1 or 4 to 23.
  • Such numbers of substitutions and/or insertions and/or deletions and/or percentage homology may be taken over the entire length of the polynucleotide or over 50, 30, 15, 10 or less flanking nucleotides in total or on each side.
  • the polynucleotide may be RNA or DNA, including genomic DNA, synthetic DNA or cDNA.
  • the polynucleotide may be single or double stranded.
  • the polynucleotide may comprise synthetic or modified nucleotides, such as methylphosphonate and phosphoro hioate backbones or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
  • a polynucleotide of the invention may be used as a primer, for example for PCR, or a probe.
  • a polynucleotide or polypeptide of the invention may carry a revealing label.
  • Suitable labels include radioisotopes such as 32 P or 35 S, fluorescent labels, enzyme labels or other protein labels such as biotin.
  • the invention also provides expression vectors that comprise polynucleotides of the invention and are capable of expressing a polypeptide of the invention.
  • Such vectors may also comprise appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression.
  • the coding sequence in the vector is operably linked to such elements so that they provide for expression of the coding sequence (typically in a cell).
  • operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • the vector may be for example plasmid, virus or phage vector. Typically the vector has an origin of replication.
  • the vector may comprise one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a resistance gene for a fungal vector.
  • Vectors may be used in vitro, for example for the production of DNA or RNA or used to transfect or transform a host cell, for example, a mammalian host cell.
  • the vectors may also be adapted to be used in vivo, for example in a method of gene therapy.
  • Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed.
  • yeast promoters include S. cerevisiae GAL4 and ADH promoters, S. pombe nmt and adh promoter.
  • Mammalian promoters include the metallothionein promoter which can be induced in response to heavy metals such as cadmium.
  • Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used.
  • Mammalian promoters, such as ⁇ -actin promoters may be used. Tissue-specific promoters are especially preferred.
  • Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the S V40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSN promoters (such as the HSV IE promoters), or HPV promoters, particularly the HPV upstream regulatory region (URR).
  • MMLV LTR Moloney murine leukaemia virus long terminal repeat
  • RSV rous sarcoma virus
  • S V40 the human cytomegalovirus
  • CMV human cytomegalovirus
  • HSN promoters such as the HSV IE promoters
  • HPV promoters particularly the HPV upstream regulatory region (URR).
  • the vector may further include sequences flanking the polynucleotide giving rise to polynucleotides which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences.
  • sequences flanking the polynucleotide giving rise to polynucleotides which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences.
  • sequences flanking the polynucleotides which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences.
  • viral vectors include herpes simplex viral vectors and retroviruses, including lentiviruses, adenoviruses, adeno-associated viruses and HPV viruses. Gene transfer techniques using these viruses are known to those skilled in the art. Retrovirus vectors for example may be used to stably integrate the polynucleotide giving rise to the polynucleotide into the host genome. Replication-defective adenovirus vectors by contrast remain episomal and therefore allow transient expression.
  • the polynucleotide may be a probe or primer which is capable of selectively binding to a breed-specific S ⁇ P.
  • the probe or primer is capable of selectively binding to a S ⁇ P position as identified in any one of SEQ ID ⁇ O:s 1 or 4 to 23.
  • the probe or primer more preferably comprises a fragment of a nucleic acid sequence of any one of SEQ ID NO:s 1 or 4 to 23 which comprises the SNP position.
  • the invention thus provides a probe or primer for use in a method according to the invention, which probe or primer is capable of selectively detecting the presence of a breed-specific SNP.
  • the probe is isolated or recombinant nucleic acid. Preferably it is at least 10, 15, 20 or 25 bases in length. It may correspond to or be antisense to the sequences set out in any one of SEQ ID NO:s 1 or 4 to 23.
  • the probe may be immobilised on an array, such as a polynucleotide array.
  • polypeptides, polynucleotides, vectors, cells or antibodies of the invention may be present in an isolated or substantially purified form. They may be mixed with carriers or diluents which will not interfere with their intended use and still be regarded as substantially isolated. They may also be in a substantially purified form, in which case they will generally comprise at least 90%, e.g. at least 95%, 98%> or 99%, of the proteins, polynucleotides, cells or dry mass of the preparation.
  • any of the above features that relate to polynucleotides - and proteins may also be a feature of the other polypeptides and proteins mentioned herein, such as the polypeptides and proteins used in the screening and therapeutic aspects of the invention.
  • such features may be any of the lengths, modifications and vectors forms mentioned above.
  • homologues of polynucleotide or protein sequences are referred to herein.
  • Such homologues typically have at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99%> homology, for example over a region of at least 15, 20, 30, 100 more contiguous nucleotides or amino acids.
  • the homology may be calculated on the basis of nucleotide or amino acid identity (sometimes referred to as "hard homology").
  • the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395).
  • the PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent or corresponding sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10.
  • HSPs high scoring sequence pair
  • Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
  • the BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787.
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two polynucleotide or amino acid sequences would occur by chance.
  • P(N) the smallest sum probability
  • a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • the homologous sequence typically differs by at least 1, 2, 5, 10, 20 or more mutations (which may be substitutions, deletions or insertions of nucleotide or amino acids). These mutations may be measured across any of the regions mentioned above in relation to calculating homology. In the case of proteins the substitutions are preferably conservative substitutions. These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
  • the invention also provides antibodies specific for a polypeptide of the invention.
  • the antibodies include those which are specific for proteins which have a breed-specific SNP, such as any of the SNPs mentioned herein, but which do not bind to protein sequences that do not contain the breed-specific SNP.
  • the antibodies of the invention are for example useful in purification, isolation or screening methods involving immunoprecipitation techniques.
  • Antibodies may be raised against specific epitopes of the polypeptides of the invention.
  • An antibody, or other compound "specifically binds" to a polypeptide when it binds with preferential or high affinity to the protein for which it is specific but does substantially bind not bind or binds with only low affinity to other polypeptides.
  • a variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of an antibody are well known in the art (see for example Maddox et al, J. Exp. Med. 158, 1211-1226, 1993). Such immunoassays typically involve the formation of complexes between the specific protein and its antibody and the measurement of complex formation.
  • the term "antibody”, unless specified to the contrary, includes fragments which bind a polypeptide of the invention. Such fragments include Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies. Furthermore, the antibodies and fragment thereof may be chimeric antibodies, CDR- grafted antibodies or humanised antibodies.
  • Antibodies may be used in a method for detecting polypeptides of the invention in a biological sample (such as any such sample mentioned herein), which method comprises:
  • Antibodies of the invention can be produced by any suitable method.
  • Means for preparing and characterising antibodies are well known in the art, see for example Harlow and Lane (1988) "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  • an antibody may be produced by raising antibody in a host animal against the whole polypeptide or a fragment thereof, for example an antigenic epitope thereof, herein after the "immunogen".
  • the fragment may be any of the fragments mentioned herein (typically at least 10 or at least 15 amino acids long) and comprise a SNP marker (such as any of the SNP markers mentioned herein).
  • a method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the animal's serum.
  • the animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified.
  • a method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody.
  • Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein (1975) Nature 256, 495-497).
  • An immortalized cell producing the desired antibody may be selected by a conventional procedure.
  • the hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host.
  • Human antibody may be prepared by in vitro immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.
  • the experimental animal is suitably a goat, rabbit, rat, mouse, guinea pig, chicken, sheep or horse.
  • the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier.
  • the carrier molecule is typically a physiologically acceptable carrier.
  • the antibody obtained may be isolated and, if desired, purified.
  • the invention also provides a kit that comprises means for determining the nucleotide present at one or more breed specific genomic SNP positions in a dog.
  • such means may include a specific binding agent, probe, primer, pair or combination of primers, or antibody, including an antibody fragment, as defined herein which is capable of detecting or aiding detection of a breed-specific SNP.
  • the primer or pair or combination of primers may be sequence specific primers which only cause PCR amplification of a polynucleotide sequence comprising a particular nucleotide at the SNP position, as discussed herein.
  • the means for determining nucleotide present at one or more breed specific SNP positions may be provided in containers that are labelled with the breed for which the SNP is specific.
  • the kit may further comprise buffers or aqueous solutions.
  • the kit may additionally comprise one or more other reagents or instruments which enable any of the embodiments of the method mentioned above to be carried out.
  • reagents or instruments may include one or more of the following: a means to detect the binding of the agent to the SNP, a detectable label such as a fluorescent label, an enzyme able to act on a polynucleotide, typically a polymerase, restriction enzyme, ligase, RNAse H or an enzyme which can attach a label to a polynucleotide, suitable buffer(s) or aqueous solutions for enzyme reagents, PCR primers which bind to regions flanking the SNP position as discussed herein, a positive and/or negative control, a gel electrophoresis apparatus, a means to isolate DNA from a sample, a means to obtain a sample from the individual, such as swab or an instrument comprising a needle, or a support comprising wells on which detection reactions can be carried out.
  • the kit may be, or
  • the invention relates to a customised diet for a dog based on its nutritional needs, as determined by its breed inheritance.
  • a food may be in the form of, for example, wet pet foods, semi-moist pet foods, dry pet foods and pet treats.
  • Wet pet food generally has a moisture content above 65%>.
  • Semi-moist pet food typically has a moisture content between 20-65% and can include humectants and other ingredients to prevent microbial growth.
  • Dry pet food also called kibble, generally has a moisture content below 20% and its processing typically includes extruding, drying and/or baking in heat.
  • Pet treats can be semi-moist, chewable treats; dry treats; chewable bones; baked, extruded or stamped treats; or other types of treats which are known in the art.
  • the ingredients of a dry pet food generally include cereal, grains, meats, poultry, fats, vitamins and minerals.
  • the ingredients are typically mixed and put through an extruder/cooker.
  • the product is then typically shaped and dried, and after drying, flavours and fats may be coated or sprayed onto the dry product.
  • All pet food is required to provide a certain level of nutrients.
  • AAFCO Association of American Feed Control Officials
  • Pet Food Institute have established nutrient profiles for dog foods, based on commonly used ingredients. These established profiles are called the "AAFCO dog food nutrient profiles”. Under these regulations, dog foods must be formulated to contain concentrations of nutrients that meet all minimum levels and not to exceed the maximum levels as determined by AAFCO.
  • the AAFCO nutritional guideline provides adequate nutrition but may not provide the dog with optimal nutrition. For this reason, dog food formulations have been developed which meet the specific needs of various dog breeds or breed categories.
  • a breed specific diet for the Bedlington Terrier typically comprises a dry product containing 18% protein, 18% fat, 7% ash, 2% fibre, and a wet product containing 8% protein, 5% fat, 1% ash and 2% fibre.
  • the ingredients used are typically chicken, cereals and byproducts, and supplementary vitamins, minerals, and amino acids.
  • the present invention enables the preparation of customised dog food, wherein one or more nutritional requirements of the dog is determined by a method of the invention, a customised dog food formulation that corresponds to the nutritional requirements of the dog is generated, and a dog food according to the customised dog food formulation is prepared.
  • the preparation of customised dog food may be carried out by electronic means, for example by using a computer system.
  • the dog food formulation may be customised according to the caloric, protein, fat, carbohydrate, fibre, vitamin or mineral requirements of the dog, as discussed herein.
  • the dog food formulation may be customised to provide the correct amounts or ratio of essential fatty acids such as omega-6 and omega-3 fatty acids.
  • the main sources of omega-6 fatty acids are plants such as sunflower, soyabean oil, safflower and evening primrose oil, whereas omega-3 fatty acids are mainly found in linseed and marine sources, for example canola oil and salmon oil.
  • the customised dog food formulation comprises components suitable for the breed(s) which have contributed to the genetic breed inheritance of the dog, and does not comprise components that are not suitable for the breed(s) which have contributed to the genetic breed inheritance of the dog.
  • the customised food does not contain ingredients which are poorly tolerated or cause allergies, are abnormally processed or stored, or contribute to diseases or conditions typically suffered by the breed(s) which have contributed to the genetic breed inheritance of the dog.
  • the customised food contains ingredients which are commonly lacking in, or have nutritional or medical benefits for the breed(s) which have contributed to the genetic breed inheritance of the dog.
  • the customised food may be formulated so that it does not contain ingredients that are poorly tolerated or cause allergies, for example gluten- containing grains such as wheat, particular protein sources such as animal proteins, milk (lactose), eggs, soy, peanuts, shellfish, fruits or tree nuts.
  • the customised food formulation may further exclude ingredients that are abnormally processed or stored or contribute to diseases or conditions, for example copper, saturated fats and salt.
  • the customised food may be formulated to include functional ingredients that help prevent disease or have other beneficial effects for the dog, such as: vitamins, minerals, cocoa flavanols, other plant flavanols, lycopene, curcumin, minerals, trace metals, Echineacea, phosphatidyl serine, L-arginine, ginseng, psyllium, prebiotics, probiotics, phyto-oestrogens, phyto-chemicals, soluble fibre, PUFAs, phospholipids, omega-6 and omega-3 fatty acids.
  • functional ingredients that help prevent disease or have other beneficial effects for the dog, such as: vitamins, minerals, cocoa flavanols, other plant flavanols, lycopene, curcumin, minerals, trace metals, Echineacea, phosphatidyl serine, L-arginine, ginseng, psyllium, prebiotics, probiotics, phyto-oestrogens, phyto-chemicals, soluble fibre, PUFAs,
  • the present invention also relates to a method of providing a customised dog food, comprising providing to:
  • a method of feeding a dog comprising feeding a mixture of foods that have been formulated for specific breeds or breed categories, based on the dog's genetic breed inheritance. For example, an outbred dog that has breed-specific markers for two different breeds could be fed a mixture of breed-specific food formulations for those two breeds.
  • a dog that showed the presence of breed-specific markers from one or more breeds in a particular category could be fed food that had been formulated for that breed category. It may be that the nutritional requirements of one of the breeds from which a crossbred or outbred dog is derived is dominant over the one or more other breeds represented in the dog. In that case, the customised food may be tailored to meet the requirements of the dominant breed. Alternatively, the food may be customised according to the proportion of genetic inheritance from each breed represented.
  • the invention provides a method of treating a dog for a disease that occurs in a dog breed, comprising identifying a disease susceptibility by a method of the invention, and administering to the dog an effective amount of a therapeutic agent which prevents or treats the disease.
  • the therapeutic agent is typically a drug such as an anti-inflammatory, antibiotic, vasodilator, calcium blocker, vaccine, insecticide or hormone.
  • the therapeutic agent may be a drug such as an antihistamine, tranquilizer, mood stabilizer, anticonvulsant, progestin, antidepressant, anxiolytic or narcotic.
  • the therapeutic agent may be administered in various manners such as orally, intracranially, intravenously, intramuscularly, intraperitoneally, intranasally, intrademally, and subcutaneously.
  • the pharmaceutical compositions that contain the therapeutic agent will normally be formulated with an appropriate pharmaceutically acceptable carrier or diluent depending upon the particular mode of administration being used.
  • parenteral formulations are usually injectable fluids that use pharmaceutically and physiologically acceptable fluids such as physiological saline, balanced salt solutions, or the like as a vehicle.
  • Oral formulations may be solids, e.g. tablets or capsules, or liquid solutions or suspensions.
  • a typical daily dose is from about 0.1 to 50 mg per kg, preferably from about O.lmg/kg to lOmg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration.
  • daily dosage levels are from 5 mg to 2 g.
  • the sequences of the breed-specific SNPs may be stored in an electronic format, for example in a computer database.
  • the invention provides a database comprising information relating to breed-specific genomic SNPs.
  • the database may include further information about the SNP, for example the level of association of the SNP marker with the breed or the frequency of the SNP in the breed.
  • the database may optionally comprise information relating to the nutritional requirements, disease susceptibility or behavioural characteristics of the breeds for which the SNPs are specific.
  • the database further comprises information regarding the food components which are suitable and the food components which are not suitable for the breeds for which the SNPs are specific.
  • a database as described herein may be used to determine the breed inheritance of a dog. Such a determination may be carried out by electronic means, for example by using a computer system (such as a PC). Typically, the determination will be carried out by inputting genetic data from the dog to a computer system; comparing the genetic data to a database comprising information relating to breed-specific genomic SNPs; and on the basis of this comparison, determining the nucleotide present at one or more breed-specific SNP positions, thereby identifying the breed inheritance of the dog.
  • a method for determining the nutritional requirements, disease susceptibility or behavioural characteristics of a dog according to the invention may also be carried out by electronic means, for example by using a computer system (such as a PC).
  • the method will comprise inputting data of the breed-specific genomic SNPs present in the dog to a computer system; comparing this data to a database which comprises information relating to breed- specific genomic SNPs and the nutritional requirements, disease susceptibility or behavioural characteristics of the breeds; and determining on the basis of the comparison the nutritional requirements, disease susceptibility or behavioural characteristics of the dog.
  • the invention also provides a computer program comprising program code means for performing all the steps of a method of the invention when said program is run on a computer. Also provided is a computer program product comprising program code means stored on a computer readable medium for performing a method of the invention when said program is run on a computer. A computer program product comprising program code means on a carrier wave that, when executed on a computer system, instruct the computer system to perform a method of the invention is additionally provided.
  • the invention also provides an apparatus arranged to perform a method according to the invention.
  • the apparatus typically comprises a computer system, such as a PC.
  • the computer system comprises: means 20 for receiving data of breed-specific genomic SNP markers; a module 30 for comparing the data with a database 10 comprising information relating to breed- specific genomic SNPs and optionally the nutritional requirements, disease susceptibility or behavioural characteristics of the breeds; and means 40 for determining on the basis of said comparison the breed inheritance and optionally the nutritional requirements, disease susceptibility or behavioural characteristics of the dog.
  • the manufacture of a customised dog food may be controlled electronically.
  • the nutritional requirements of the dog may be processed electronically to generate a customised dog food formulation.
  • the customised dog food formulation may then be used to generate electronic manufacturing instructions to control the operation of food manufacturing apparatus.
  • the apparatus used to carry out these steps will typically comprise a computer system, such as a PC, which comprises means 50 for processing the nutritional requirement information to generate a customised dog food formulation; means 60 for generating electronic manufacturing instructions to control the operation of food manufacturing apparatus; and a food product manufacturing apparatus 70.
  • the food product manufacturing apparatus used in the present invention typically comprises one or more of the following components: container for dry pet food ingredients; container for liquids; mixer; former and/or extruder; cut-off device; cooking means (e.g. oven); cooler; packaging means; and labelling means.
  • a dry ingredient container typically has an opening at the bottom. This opening may be covered by a volume-regulating element, such as a rotary lock. The volume- regulating element may be opened and closed according to the electronic manufacturing instructions to regulate the addition of dry ingredients to the pet food. Dry ingredients typically used in the manufacture of pet food include corn, wheat, meat and/or poultry meal. Liquid ingredients typically used in the manufacture of pet food include fat, tallow and water.
  • a liquid container may contain a pump that can be controlled, for example by the electronic manufacturing instructions, to add a measured amount of liquid to the pet food.
  • the dry ingredient container(s) and the liquid container(s) are coupled to a mixer and deliver the specified amounts of dry ingredients and liquids to the mixer.
  • the mixer may be controlled by the electronic manufacturing instructions. For example, the duration or speed of mixing may be controlled.
  • the mixed ingredients are typically then delivered to a former or extruder.
  • the former/extruder may be any former or extruder known in the art that can be used to shape the mixed ingredients into the required shape.
  • the mixed ingredients are forced through a restricted opening under pressure to form a continuous strand. As the strand is extruded, it may be cut into pieces (kibbles) by a cut-off device, such as a knife.
  • the kibbles are typically cooked, for example in an oven.
  • the cooking time and temperature may be controlled by the electronic manufacturing instructions. The cooking time may be altered in order to produce the desired moisture content for the food.
  • the cooked kibbles may then be transferred to a cooler, for example a chamber containing one or more fans.
  • the pet food manufacturing apparatus may comprise a packaging apparatus.
  • the packaging apparatus typically packages the pet food into a container such as a plastic or paper bag or box.
  • the apparatus may also comprise means for labelling the pet food, typically after the food has been packaged.
  • the label may provide information such as: ingredient list; nutritional information; date of manufacture; best before date; weight; and breed(s) or breed category or sub-group for which the food is suitable.
  • a labelled dog food product wherein the food product is customised for one or more breed(s) and the label provides an indication of one or more breed specific genomic SNP marker(s) present in said breed(s).
  • Example 1 The invention is illustrated by the following Examples: Example 1
  • Buccal cells were collected from 72 dogs of 16 different breeds by scraping the inside cheek six times with a sterile cytology brush (Rocket Medical, Cat No. R57483), ensuring that the animal providing the sample had not consumed any food or drink for 30min prior to sample collection. The brushes were then replaced in their individual wrappers and left to dry for a minimum of 2 hours at room temperature. DNA was extracted using standard techniques (Qiagen's QIAamp DNA Blood Mini Kit, Cat No. 51104) following the Buccal Swab Spin protocol. The DNA was then stored at -20°C.
  • the primers used were designed to amplify products ranging from 200-600bp in length.
  • the primers were designed by eye, and were made to be approximately 20bp in length, with approximately 50%o G/C, 50%) A T ratio. These were ordered from Sigma-Genosys, desalted, and at 0.025 ⁇ M synthesis scale.
  • 12.5ng of genomic dog DNA (Gibco, Cat. 69234) was added to 12.5ng of DNA from each dog and was amplified up in 25 ⁇ l PCR reactions with Eurogentec HotGoldstar PCR mastermix (PK-0073-02). Reactions contained 1.5mM MgCl 2 and 25pmol of each primer.
  • Thermal cycling was performed using a Hybaid MBS 0.2S PCR machine using the following cycling conditions: an initial incubation of 95°C for 10 min, followed by 30 cycles of 95°C for 30 sec, 60°C for 45 sec and 72°C for 90 sec. This was followed by a final extension step of 72°C for 5 min.
  • the base sequence of the wild- type amplicon was manually inputted into the Transgenomic Wave Machine, and the PCR products run according to the manufacturers directions as described in the WAVEMAKER Software Manual, Transgenomic Inc. 1999, version 2.0 Oct 1999. Chromatograms were examined for the presence of additional peaks indicating the presence of a single nucleotide polymorphism in the sample.
  • the PCR amplification described above was repeated on the DNA samples indicated to have SNPs present, with the following change: 25ng of the test DNA sample was added to the PCR reaction, and no other DNA was added.
  • the PCR products were then purified using a Qiagen PCR Purification Kit (Cat No. 28104), following the method Qiaquick PCR Purification using a microcentrifuge.
  • Cycle sequencing was performed using 25fmol of purified PCR product with the CEQ 2000 Dye Terminator Cycle Sequencing with Quick Start Kit (Beckman Coulter, P/N 608120). 20 ⁇ l reactions were prepared as described in the manufacturers directions using the same primers used in the PCR step, and were subjected to 30 cycles at 95°C for 20 sec, 60°C for 20 sec and 72°C for 4 min. Following these cycles, the samples were subjected to ethanol precipitation, and were evaporated to dryness using a vacuum pump for approximately 40 min. The samples were then resuspended in 40 ⁇ l of deionised formamide and a drop of mineral oil was placed on top. The samples were then run on a Beckman CEQ 2000 Sequencer using the LFR capillary method. SNPs were called using the CEQ2000XL DNA Analysis System Software Version 4.3.9, and were confirmed using the reverse traces.
  • a SNP was identified in the mast cell chymase gene of the breed English Mastiff at position 5375.
  • the SNP is shown as underlined in the sequence below (SEQ ID NO: 1).
  • the position 5375 is defined using standard nomenclature as can be seen in accession NCBI Ref U89607.
  • the following primers were used for PCR amplification:
  • Dog genomic DNA was acquired from various sources. In total, 51 dogs were included in the study: 5 German Shepherds, 6 Rottweilers, 6 Daschunds, 6 Cocker Dogls, 6 Golden Retrievers, 2 Poodles, 2 Beagles, 6 England Terriers, 6 Shih Tzus and 6 Labrador s.
  • blastn nucleotide-nucleotide blast
  • blastx translated query vs protein database
  • Primers were manually designed along the contig at 600 bp spacing. The forward primer of each amplicon was located approximately 50 bp before the reverse primer of the previous amplicon. Primer design was concentrated around exonic regions and away from repeat regions. Primers were approximately 20 bases long with a melting temperature between 56°C and 64°C. The primers were ordered desalted at a synthesis scale of 0.025 ⁇ M (Sigma-Genosys).
  • 25 ⁇ l PCR reactions were carried using 25 pmol of each primer, 25 ng of commercial dog genomic DNA (Novegen, Cat. No 69234) and 12.5 ⁇ l of Eurogentec HotGoldstar PCR mastermix containing a red loading dye and 1.5 mM MgCl (PK- 0073-02R).
  • Thermal cycling was performed using a Hybrid MBS 0.2S PCR machine using the following cycling conditions: incubation at 95°C for 10 mins, 10 cycles of 95°C for 30 seconds, followed by 64°C (minus 1°C per cycle) for 45 seconds and 72°C for 90 seconds, and 28 cycles of 95°for 30 seconds, 55°C for 45 sec and 72°C for 90 seconds.
  • PolyPhred In order to identify SNPs (single nucleotide polymorphisms) the PolyPhred computer programme was employed. PolyPhred automatically detects the presence of heterozygous single nucleotide substitutions by comparing the pattern of the fluorescence dye incorporation between traces (Nickerson et al. Nucleic Acids Research 25 (14):2745-2751, 1997). PolyPhred is not used alone but in conjuction with Phred automated base calling, Phrap sequence assembly and Consed sequence assembly editing. The output from PolyPhred was then reformatted for the genetic algorithm software (G-max).
  • the objective of the next stage was to derive a way of determining breed status using a pattern of SNPs found via sequencing.
  • the Gmax software http://www.theqmax.com/) uses a genetic algorithm to extract such patterns from large data sets.
  • the pattern is extracted in the form of a rule.
  • Each rule is expressed as a Boolean formula, where "&" is “AND”, “
  • Gmax was used to screen thousands of SNPs to find a combination of a smaller number that define the breed well. For example, using 5 SNPs from a possible 1000, there will be 10 17 possible combinations to search through. Randomly picking rules to fit the data would not work very well. However, a fitness test can determine how well a random rule performs at separating the data and comparing it to how close to a solution it is. If small changes are made to the rule and retest a second score for a new rule is generated. A continuation of this process will evolve the rule. This way of working is called 'hill climbing'. The problem with hill climbing is that for complex fitness tests there are local maximums. If a local maximum is reached then the overall solution will not be found. A genetic algorithm solves this problem by keeping a large population of rules and applying a form of Darwinian evolution. Results
  • Tables 3 to 6 show the rules for each breed in the form of a Boolean formula.
  • Table 7 shows the sequences surrounding each SNP, and which bases may be present at each polymorphic position (options). The full name of each gene is abbreviated as follows:
  • FCGR2A FC gamma receptor Rlla
  • FCGR3B FC gamma receptor RHIb
  • - PAI1 plasminogen activator inhibitor 1.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Husbandry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé permettant d'évaluer un besoin nutritionnel, une prédisposition à une pathologie ou une caractéristique comportementale d'un chien. La méthode comprend les étapes suivantes : (a) déterminer le nucléotide présent en une ou plusieurs positions SNP dans le génome du chien ; (b) identifier sur cette base l'héritage génétique de la race du chien ; (c) déterminer sur la base de ces résultats, un besoin nutritionnel, une prédisposition à un pathologie ou une caractéristique comportementale du chien.
PCT/GB2004/002559 2003-06-16 2004-06-16 Essai de genotype WO2004113570A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006516424A JP2007528205A (ja) 2003-06-16 2004-06-16 遺伝子型試験
EP04736923A EP1636377A2 (fr) 2003-06-16 2004-06-16 Essai de genotype pour les chiens
AU2004249943A AU2004249943B8 (en) 2003-06-16 2004-06-16 Genotype test
US11/303,853 US20060147962A1 (en) 2003-06-16 2005-12-16 Genotype test

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0313964.9 2003-06-16
GBGB0313964.9A GB0313964D0 (en) 2003-06-16 2003-06-16 Genotype test

Publications (2)

Publication Number Publication Date
WO2004113570A2 true WO2004113570A2 (fr) 2004-12-29
WO2004113570A3 WO2004113570A3 (fr) 2005-05-26

Family

ID=27636670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002559 WO2004113570A2 (fr) 2003-06-16 2004-06-16 Essai de genotype

Country Status (5)

Country Link
EP (1) EP1636377A2 (fr)
JP (1) JP2007528205A (fr)
AU (1) AU2004249943B8 (fr)
GB (1) GB0313964D0 (fr)
WO (1) WO2004113570A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026512A2 (fr) 2004-08-30 2006-03-09 Hill's Pet Nutrition, Inc. Conception de regime alimentaire basee sur le genome
WO2006113752A1 (fr) 2005-04-19 2006-10-26 Hill's Pet Nutrition, Inc. Methodes et compositions de prevention et traitement de maladies renales
WO2007002836A2 (fr) 2005-06-29 2007-01-04 Hill's Pet Nutrition, Inc. Procedes et compositions pour la prevention et le traitement de maladie renale
WO2007022344A2 (fr) 2005-08-17 2007-02-22 Hill's Pet Nutrition, Inc. Procedes et compositions permettant de prevenir et de traiter les maladies renales
WO2007031792A1 (fr) * 2005-09-16 2007-03-22 Mars Incorporated Desmodontite du chien
WO2007063313A2 (fr) * 2005-11-30 2007-06-07 Mars, Incorporated Alleles du cmh
WO2008015436A2 (fr) * 2006-08-01 2008-02-07 Mars, Incorporated Test de diabète
WO2009044152A3 (fr) * 2007-10-03 2009-07-16 Mars Inc Test génétique et régime d'animaux domestiques
JP2010502198A (ja) * 2006-09-01 2010-01-28 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物用食物組成物を設計するための方法およびシステム
WO2010038032A1 (fr) * 2008-10-03 2010-04-08 Mars, Incorporated Test génétique de prédisposition à l'accumulation de cuivre dans le foie chez le chien et régime à faible teneur en cuivre pour animaux de compagnie
JP2010522537A (ja) * 2006-11-30 2010-07-08 ナビジェニクス インコーポレイティド 遺伝子分析系および方法
US7865343B2 (en) 1999-10-15 2011-01-04 Dodds W Jean Method of analyzing nutrition for a canine or feline animal
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
US8060354B2 (en) 1999-10-15 2011-11-15 Hemopet System and method for determining a nutritional diet for a canine or feline animal
US8224587B1 (en) 1999-10-15 2012-07-17 Hemopet Method and system for determining a nutritional diet for a canine or feline animal
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
US9808027B2 (en) 2005-05-20 2017-11-07 Colgate-Palmolive Company Methods for promoting health or wellness in adult animals
US9827314B2 (en) 2003-12-08 2017-11-28 Mars, Incorporated Edible compositions which are adapted for use by a companion animal
US10150997B2 (en) 2011-12-06 2018-12-11 Mars, Incorporated Genetic test for liver copper accumulation in dogs
KR102185440B1 (ko) * 2019-10-01 2020-12-01 대한민국 개의 고콜레스테롤혈증 조기 예측 또는 진단용 조성물

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101700622B1 (ko) * 2014-11-11 2017-02-01 대한민국 개의 품종 식별을 위한 dna 마커 및 이를 이용한 개 품종 식별방법
CN107868820B (zh) * 2017-10-26 2021-02-12 深圳深知生物科技有限公司 犬类多重遗传病筛查的引物组和试剂盒

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008720A2 (fr) * 1999-07-30 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Hypocretine et recepteurs d'hypocretine pour la regulation du sommeil et des troubles du sommeil
US6210897B1 (en) * 1999-05-26 2001-04-03 Leif Andersson Identification of canine leukocyte adhesion deficiency in dogs
WO2001084950A1 (fr) * 2000-05-08 2001-11-15 The Iams Company Composition dietetique hypoallergenique et procede permettant de diagnostiquer des allergies alimentaires chez des animaux de compagnie
US20020081356A1 (en) * 1999-01-15 2002-06-27 Bebiak David M. Methods for customizing pet food
WO2002102172A1 (fr) * 2001-06-15 2002-12-27 Nestec Ltd. Procedes et appareil de personnalisation d'aliments pour animaux familiers
US6524609B1 (en) * 1999-08-18 2003-02-25 Nutri-Vet, Llc Treating arthritis in animals with dietary supplements
EP1454915A1 (fr) * 2002-12-24 2004-09-08 President of Gifu University Polynucleotides, polypeptides et methode pour tester des chiens candidats utiles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720014B1 (en) * 1997-08-13 2004-04-13 Diversa Corporation Phytase-containing foodstuffs and methods of making and using them
JP2003506074A (ja) * 1999-08-09 2003-02-18 ジェネッサンス ファーマシューティカルズ，インコーポレイティド 薬剤標的同質遺伝子：免疫グロブリンｅ受容体ｉａｌｐｈａサブユニット遺伝子における多型

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081356A1 (en) * 1999-01-15 2002-06-27 Bebiak David M. Methods for customizing pet food
US6210897B1 (en) * 1999-05-26 2001-04-03 Leif Andersson Identification of canine leukocyte adhesion deficiency in dogs
WO2001008720A2 (fr) * 1999-07-30 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Hypocretine et recepteurs d'hypocretine pour la regulation du sommeil et des troubles du sommeil
US6524609B1 (en) * 1999-08-18 2003-02-25 Nutri-Vet, Llc Treating arthritis in animals with dietary supplements
WO2001084950A1 (fr) * 2000-05-08 2001-11-15 The Iams Company Composition dietetique hypoallergenique et procede permettant de diagnostiquer des allergies alimentaires chez des animaux de compagnie
WO2002102172A1 (fr) * 2001-06-15 2002-12-27 Nestec Ltd. Procedes et appareil de personnalisation d'aliments pour animaux familiers
EP1454915A1 (fr) * 2002-12-24 2004-09-08 President of Gifu University Polynucleotides, polypeptides et methode pour tester des chiens candidats utiles

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BROUILLETTE J A ET AL: "Within-breed heterozygosity of canine single nucleotide polymorphisms identified by across-breed comparison." ANIMAL GENETICS, vol. 33, no. 6, December 2002 (2002-12), pages 464-467, XP002297778 ISSN: 0268-9146 *
BROUILLETTE JAMES A ET AL: "Estimate of nucleotide diversity in dogs with a pool-and-sequence method" MAMMALIAN GENOME, vol. 11, no. 12, December 2000 (2000-12), pages 1079-1086, XP002297779 ISSN: 0938-8990 *
CAUGHEY G H ET AL: "Cloning and expression of the dog mast cell alpha-chymase gene." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 NOV 1997, vol. 159, no. 9, 1 November 1997 (1997-11-01), pages 4367-4375, XP002297781 ISSN: 0022-1767 *
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, PEARCE-KELLING S E ET AL: "Test Matings Confirm Allelism Of prcd Across Many Dog Breeds." XP002297784 Database accession no. PREV200300165155 & ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, page Abstract No. 3673, ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FLORIDA, USA; MAY 05-10, 2002 *
IRION D N ET AL: "Analysis of genetic variation in 28 dog breed populations with 100 microsatellite markers." JOURNAL OF HEREDITY, vol. 94, no. 1, 1 February 2003 (2003-02-01), pages 81-87, XP009036762 ISSN: 0022-1503 *
KIJAS J M H ET AL: "Detection of the causal mutation for canine leukocyte adhesion deficiency (CLAD) using pyrosequencing" ANIMAL GENETICS, vol. 31, no. 5, October 2000 (2000-10), pages 326-328, XP002297788 ISSN: 0268-9146 *
LAFOND E ET AL: "BREED SUSCEPTIBILITY FOR DEVELOPMENTAL ORTHOPEDIC DISEASES IN DOGS" JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, AMERICAN ANIMAL HOSPITAL ASSOCIATION, MISHAWAKA,, US, vol. 38, no. 5, September 2002 (2002-09), pages 467-477, XP009036996 ISSN: 0587-2871 *
MASUDA KOJI ET AL: "Breed differences in genotype and allele frequency of catechol O-methyltransferase gene polymorphic regions in dogs." JOURNAL OF VETERINARY MEDICAL SCIENCE, vol. 66, no. 2, February 2004 (2004-02), pages 183-187, XP002297782 ISSN: 0916-7250 *
NIIMI Y ET AL: "BREED DIFFERENCES IN ALLELE FREQUENCY OF THE DOPAMINE RECEPTOR D4 GENE IN DOGS" JOURNAL OF HEREDITY, OXFORD UNIVERSITY PRESS, CARY, GB, vol. 92, no. 5, September 2001 (2001-09), pages 433-436, XP009032482 ISSN: 0022-1503 *
PARKER HEIDI G ET AL: "Genetic structure of the purebred domestic dog" SCIENCE (WASHINGTON D C), vol. 304, no. 5674, 21 May 2004 (2004-05-21), pages 1160-1164, XP002297783 ISSN: 0036-8075 *
PELLEGRINI B ET AL: "Cloning and characterization of opticin cDNA: evaluation as a candidate for canine oculo-skeletal dysplasia" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 282, no. 1-2, 9 January 2002 (2002-01-09), pages 121-131, XP004334712 ISSN: 0378-1119 *
SALAVAGGIONE ORESTE E ET AL: "Canine red blood cell thiopurine S-methyltransferase: Companion animal pharmacogenetics." PHARMACOGENETICS, vol. 12, no. 9, December 2002 (2002-12), pages 713-724, XP009036995 ISSN: 0960-314X *
SWANSON KELLY S ET AL: "Nutritional genomics: Implications for companion animals." JOURNAL OF NUTRITION, vol. 133, no. 10, October 2003 (2003-10), pages 3033-3040, XP002312349 ISSN: 0022-3166 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7865343B2 (en) 1999-10-15 2011-01-04 Dodds W Jean Method of analyzing nutrition for a canine or feline animal
US8060354B2 (en) 1999-10-15 2011-11-15 Hemopet System and method for determining a nutritional diet for a canine or feline animal
US8224587B1 (en) 1999-10-15 2012-07-17 Hemopet Method and system for determining a nutritional diet for a canine or feline animal
US8234099B2 (en) 1999-10-15 2012-07-31 Hemopet Computer program for determining a nutritional diet product for a canine or feline animal
US9827314B2 (en) 2003-12-08 2017-11-28 Mars, Incorporated Edible compositions which are adapted for use by a companion animal
US12059465B2 (en) 2003-12-08 2024-08-13 Mars, Incorporated Edible compositions
EP1794316A2 (fr) * 2004-08-30 2007-06-13 Hill's Pet Nutrition Inc. Conception de regime alimentaire base sur le genome
WO2006026512A2 (fr) 2004-08-30 2006-03-09 Hill's Pet Nutrition, Inc. Conception de regime alimentaire basee sur le genome
EP1794316A4 (fr) * 2004-08-30 2010-11-24 Hills Pet Nutrition Inc Conception de regime alimentaire base sur le genome
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
US8668922B2 (en) 2004-12-29 2014-03-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
WO2006113752A1 (fr) 2005-04-19 2006-10-26 Hill's Pet Nutrition, Inc. Methodes et compositions de prevention et traitement de maladies renales
US9272033B2 (en) 2005-04-19 2016-03-01 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
US9808027B2 (en) 2005-05-20 2017-11-07 Colgate-Palmolive Company Methods for promoting health or wellness in adult animals
WO2007002836A2 (fr) 2005-06-29 2007-01-04 Hill's Pet Nutrition, Inc. Procedes et compositions pour la prevention et le traitement de maladie renale
US9173427B2 (en) 2005-06-29 2015-11-03 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
US9149062B2 (en) 2005-06-29 2015-10-06 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
US8859613B2 (en) 2005-08-17 2014-10-14 Hill's Pet Nutrition, Inc. Compositions for the treatment of kidney disease
WO2007022344A2 (fr) 2005-08-17 2007-02-22 Hill's Pet Nutrition, Inc. Procedes et compositions permettant de prevenir et de traiter les maladies renales
US8263646B2 (en) 2005-08-17 2012-09-11 Hill's Pet Nutrition, Inc. Methods for the treatment of kidney disease
US8492432B2 (en) 2005-08-17 2013-07-23 Hill's Pet Nutrition, Inc. Methods for the treatment of kidney disease
WO2007031792A1 (fr) * 2005-09-16 2007-03-22 Mars Incorporated Desmodontite du chien
JP2009512424A (ja) * 2005-09-16 2009-03-26 マーズ インコーポレーテッド イヌの歯周炎
WO2007063313A3 (fr) * 2005-11-30 2007-07-19 Mars Inc Alleles du cmh
WO2007063313A2 (fr) * 2005-11-30 2007-06-07 Mars, Incorporated Alleles du cmh
WO2008015436A3 (fr) * 2006-08-01 2008-03-27 Mars Inc Test de diabète
WO2008015436A2 (fr) * 2006-08-01 2008-02-07 Mars, Incorporated Test de diabète
JP2010502198A (ja) * 2006-09-01 2010-01-28 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物用食物組成物を設計するための方法およびシステム
JP2014140387A (ja) * 2006-11-30 2014-08-07 Navigenics Inc 遺伝子分析系および方法
JP2010522537A (ja) * 2006-11-30 2010-07-08 ナビジェニクス インコーポレイティド 遺伝子分析系および方法
WO2009044152A3 (fr) * 2007-10-03 2009-07-16 Mars Inc Test génétique et régime d'animaux domestiques
WO2010038032A1 (fr) * 2008-10-03 2010-04-08 Mars, Incorporated Test génétique de prédisposition à l'accumulation de cuivre dans le foie chez le chien et régime à faible teneur en cuivre pour animaux de compagnie
US7970552B1 (en) 2008-12-16 2011-06-28 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
RU2564129C2 (ru) * 2009-04-08 2015-09-27 Марс, Инкорпорейтед Генетический тест на накопление меди в печени собак и корм для домашних животных с низким содержанием меди
WO2010116137A1 (fr) * 2009-04-08 2010-10-14 Mars, Incorporated Test génétique pour une accumulation de cuivre dans le foie chez les chiens, et régime alimentaire pour animaux à faible teneur en cuivre
US9415067B2 (en) 2009-04-08 2016-08-16 Mars, Incorporated Genetic test for liver copper accumulation in dogs and low copper pet diet
US10150997B2 (en) 2011-12-06 2018-12-11 Mars, Incorporated Genetic test for liver copper accumulation in dogs
KR102185440B1 (ko) * 2019-10-01 2020-12-01 대한민국 개의 고콜레스테롤혈증 조기 예측 또는 진단용 조성물

Also Published As

Publication number Publication date
GB0313964D0 (en) 2003-07-23
AU2004249943B2 (en) 2008-07-03
JP2007528205A (ja) 2007-10-11
EP1636377A2 (fr) 2006-03-22
AU2004249943A1 (en) 2004-12-29
AU2004249943B8 (en) 2008-07-10
WO2004113570A3 (fr) 2005-05-26

Similar Documents

Publication Publication Date Title
US20060147962A1 (en) Genotype test
AU2004249943B8 (en) Genotype test
US20120258183A1 (en) Macronutrient sensitivity
JP2009528064A (ja) クラス予測子を用いて肥満動物および痩身動物を同定する方法
RU2564129C2 (ru) Генетический тест на накопление меди в печени собак и корм для домашних животных с низким содержанием меди
US11559066B2 (en) Reagents, kits and methods for assessing and reducing risk of developing canine hypothyroidism and other autoimmune conditions
AU2019424830B2 (en) Methods for identifying a companion animal susceptible to treatment that reduces the risk of stone formation and compositions for reducing such risk
US20090028843A1 (en) IgA allelic variants
Dzhulamanov et al. Effect of leptin C528T and leptin C73T polymorphisms and pregnancy on adipose tissue formation and carcass grade in Aberdeen Angus heifers and first-calf cows
JP5627462B2 (ja) 遺伝子検査およびペット食
AU2019478729B2 (en) Reagents, kits and methods for assessing and reducing risk of developing canine hypothyroidism and other autoimmune conditions
CN114787387B (zh) 用于鉴定有草酸钙结石形成的风险的伴侣动物的方法和用于减少所述风险的治疗和组合物
US11559065B2 (en) Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate in canines and identifying canines at risk of such conditions
EP1954825A2 (fr) Alleles du cmh
EP1954824A1 (fr) Diabete du chien
OUCHAR et al. HaeIII Polymorphism of Growth Hormone (GH-1) Gene in Some Goat Breeds Reared in Turkey by Using PCR-RFLP Method
Lan et al. The association between apolipoprotein b2 (apob2) gene with body weight and carcass traits of noi native chickens J. Anim
CA3164484A1 (fr) Compositions et procedes de traitement et de reduction du risque d'affections associees a un niveau eleve 4-ethylphenyl sulfate chez les chiens a l'aide de pulpe de tomate et procedes d'identification de canides a risque de telles affections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006516424

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11303853

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004249943

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004736923

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004249943

Country of ref document: AU

Date of ref document: 20040616

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004249943

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004736923

Country of ref document: EP